Hollow Fibre Infection Model

Rapidly expanding facilities for in vitro PK/PD analysis in the Hollow Fibre Infection Model in BSL2

Longer study time periods leads to understanding the PK/PD relationships and the risks of the emergence of resistance in response to a given treatment

Technology:
  • Antimicrobial compound/strategy

Microorganisms:
  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

Application:
  • Human

Development stage:
  • Research
  • Development

Organization:
  • Company

Partnering:
  • Co-develop, Outsource, Joint Venture

Funding organisation:
  • CARB-X
  • GARDP
  • REPAIR

Infectious disease area:
  • UTI
  • STI
  • BSI
  • RTI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia


Life science company providing access to highly effective new therapeutics, leveraging its multimodality platform with unique innovative technologies

BSL3 high throughput screening capabilities, up to 400,000 compounds, against numerous pathogens including Mycobacterium tuberculosis.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!